The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer trial in Europe to add 11 new sites across Germany, Poland, and Spain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback